Skip to main content
. 2015 May 12;3(4):919–923. doi: 10.3892/mco.2015.565

Figure 2.

Figure 2.

(A) Overall survival (OS) and (B) disease-free survival (DFS) curves for breast cancer patients according to the expression levels of microRNA-29b (miR-29b) in estrogen receptor (ER)-positive primary tumors. The differences in OS and DFS between the miR-29b low and high expression levels were significant (P=0.013 and 0.016, respectively).